News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRANSGENE (ENX:TNG)-Tasly Pharmaceutical JV Reports Immunotherapy Progress


7/2/2014 11:52:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Transgene SA, a French immunotherapy company, reported that its 50-50 joint venture with Tianjin Tasly Pharma currently has three drug candidates in pre-clinical development. The two companies established the JV in 2010 with the goal of developing biologic drugs for the China market. Tasly is a TCM drug company. The JV’s lead product is TG1050, an adenovirus-based targeted immunotherapy aimed at treating chronic hepatitis B.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES